First Tracks Biotherapeutics begins trading on Nasdaq under TRAX ticker

• First Tracks Biotherapeutics began trading on Nasdaq Global Select Market under ticker TRAX.
• Company launched as independent public biotech focused on antibody therapies for autoimmune and inflammatory diseases.
• First Tracks Bio reported $180 million cash, citing about two-year cash runway.
• Spin-off from AnaptysBio completed via distribution of one First Tracks Bio share for each Anaptys share held on April 6 record date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-164328), on April 20, 2026, and is solely responsible for the information contained therein.